NCT03547856 A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"
| NCT ID | NCT03547856 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yan Li |
| Condition | Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2018-07-18 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2018-07-18 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population. Information of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years old * Clinical diagnosed hypertension with the use of antihypertensive drugs * A 24-hour ambulatory blood pressure monitoring was performed with validated equipment. * Willing to provide information about disease history and blood biochemical test data within 6 months. * Sign the informed consent Exclusion Criteria: * Without antihypertensive drug use * Hospitalized hypertension patients * Non-compliant patient
Contact & Investigator
Yan Li
PRINCIPAL INVESTIGATOR
Shanghai Institute of Hypertension
Frequently Asked Questions
Who can join the NCT03547856 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03547856 currently recruiting?
Yes, NCT03547856 is actively recruiting participants. Contact the research team at liyanshcn@yahoo.com for enrollment information.
Where is the NCT03547856 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT03547856 clinical trial?
NCT03547856 is sponsored by Yan Li. The principal investigator is Yan Li at Shanghai Institute of Hypertension. The trial plans to enroll 10,000 participants.